China Medical System Holdings Limited (00867.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.2x

Market Cap

HKD 26.71B

MomentumView details →

1D Return

−0.36%

YTD Return

−14.42%

RSI (14)

36.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.2x

Market Cap

HKD 26.71B

RSI (14)

36.3

MomentumView details →

1D Return

−0.36%

YTD Return

−14.42%

ProfitabilityView details →

Gross Margin

71.32%

Net Margin

19.21%

EBITDA Margin

26.05%

ROE (TTM)

17.67%

ROA (TTM)

16.12%

Asset Turnover

0.85x

GrowthView details →

Revenue YoY

+1.11%

EPS YoY

−33.33%

FCF YoY

−95.51%

Revenue CAGR 3Y

−3.54%

EPS CAGR 3Y

−22.46%

EBITDA YoY

−24.56%

EarningsView details →

EPS (Actual)

HKD 0.47

EPS Surprise

1.88%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

1.88%

Rev Surprise

−5.09%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

6.64x

Quick Ratio

5.97x

Div Yield

3.12%

Div Rate

HKD 0.34

Div Growth 1Y

+15.44%

Financials snapshotView financials →

Revenue (TTM)

16.51B

Net Income (TTM)

3.17B

Op. CF (TTM)

—

Next earningsMar 16, 2027 →

Latest newsMore news →

China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.1d ago

Elevate acquired Lupl, a legal project management platform backed by CMS, Cooley, and Rajah & Tann Asia, to expand its software business.17d ago

Similar companies

达仁堂600329.SH China Resources Pharmaceutical Group Limited03320.HK The United Laboratories International Holdings Limited03933.HK ST人福600079.SH 华海药业600521.SH Aprogen Biologics Inc.003060.KS Find similar companies →

Latest newsMore news →

China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.1d ago Elevate acquired Lupl, a legal project management platform backed by CMS, Cooley, and Rajah & Tann Asia, to expand its software business.17d ago